Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Fluticasone/Salmeterol Inhalation Powder vs. Advair Diskus in Healthy Volunteers
NCT04746040Phase 1Unknown
- Sponsor
- Respirent Pharmaceuticals Co. Ltd.
- Start
- Jan 2021
- Primary completion
- Feb 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluticasone propionate and salmeterol in asthma (2 arms), sponsored by Respirent Pharmaceuticals Co. Ltd. Primary endpoints: Maximum Plasma Concentration (Cmax) and Area Under the Curve to Last Measurable Concentration. Status: unknown.
02
Drugs
fluticasone propionatesalmeterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04746040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04746040.